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ABSTRACT 
With advancements in CRISPR-cas9 broadening the potential paths for 
clinical usage of genetic editing, conversations about genetic editing have grown to 
outside simply scientific communities and into mainstream conversations. This study 
focuses specifically on Christian discourse of genetic editing and locates four major 
tensions for many Christians when they think about genetic editing: beginning of life, 
Creator-human relationship, imago Dei, and stewardship. With these major concerns 
in mind, I identify epigenetics, somatic cell genetic editing, and in vivo genetic editing 
research as important research paths to pursue as they can potentially produce 
techniques that more Christian individuals would feel comfortable using. I pursue 
one of these paths and conclude with an experimental proposal for an analysis of in 
vivo and in vitro CIRSPR-Cas9 efficiency in regards to on- and off-target rates.  
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INTRODUCTION 
Not only is genetic editing and its rapid advancements a topic within the 
scientific community, it has been incorporated into mainstream conversations. 
Specifically, the discovery of and recent enhancements of the genetic editing 
technique, CRISPR-cas9, has made genetic editing more feasible and efficient. This 
method looks for a target sequence of DNA, using a complementary single-stranded 
guide RNA. The complex then creates a double stranded break at the target location 
and enables DNA repair off of an introduced donor DNA to replace the target 
sequence with a preferred mutation. This technique is scientifically exciting because 
of its versatility and facile targeting of a multitude of sequences. This advancement 
has shown that genetic editing could feasibly be utilized as a clinical treatment. This 
future possibility has sparked numerous discussion on whether or not we should be 
genetically editing in the first place.  
Individuals base their opinions on a variety of sources, but one major source 
that informs opinions on this moral decision is religion. Genetic editing can only be 
helpful if it is acceptable and therefore applicable to possible users. PEW conducted 
a study on the potential usage of gene-editing amongst different categories of the 
American public (Street, NW, Washington, & Inquiries, 2013). An analysis of this 
data has shown that highly religious Americans are “much more likely than those 
who are less religious to say they would not want to use gene-editing technology in 
their families”(Funk, Kennedy, & Sciupac, 2016). This is important as it highlights the 
patterns and trends within public attitudes about gene-editing and confirms the 
notion that current genetic technologies are not accessible to religious communities. 
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Since religion can be a major contributor to a person’s evaluation of genetic editing, 
if clinical benefits and care are to be extended, there is a need to develop 
techniques with which individuals can potentially agree. In addition, scholars have 
discussed the need for more conversation about genetics within faith communities 
as an attempt to answer any clarifying questions and produce a more transparent 
relationship between the two communities (Joseph, 2016). This project builds upon 
this plea for more well-informed conversations about genetics within religious 
communities, by going further and working on how the scientific community can also 
benefit by information about religious communities and not just the other way 
around. 
This thesis will look specifically at the more conservative Christian discourse 
on genetic editing and possible paths for genetic editing research that would be 
more accepted by Christian communities. The general understanding of the 
Christian stance on genetic editing is that the Christian tradition simply does not 
approve it. However, this generalization fails to account for the complexity of 
Christian concerns and the opportunity for potential acceptance within the tradition. 
In order to deduce potential acceptable paths of genetic editing, I identify four 
“tension zones” (beginning of life, Creator-human relationship, imago Dei, and 
stewardship) within the Christian discourse. These tension zones are areas within 
the discourse that are both important concerns within the Christian community, but 
also house contradictions and potential avenues for acceptance of genetic editing. I 
argue within those four tension zones, the Christian stewardship concern of harm 
and the need for the conjugal act in the creation of new life are specific areas that 
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should be taken into consideration in order to find Christian-acceptable genetic 
editing research paths: epigenetics, somatic gene therapy, and in vivo genetic 
editing. In culmination, I propose an analysis of in vivo and in vitro CRISPR-Cas9 
efficiency in regards to on- and off-target rates; on-target rates measure the amount 
of correct mutations of the intended gene sites, while off-target rates measure the 
amount of mutations of unintended gene sites. A reduction of off-target effects could 
potentially make a genetic editing method more clinically viable, as the potential 
“harm” or risk associated with the technique would be lower.  
This is a dual religious studies and biology thesis and incorporates both fields 
of study to form a comprehensive analysis of Christian discourse of genetic editing 
and its relevancy to the scientific study. A greater goal of this thesis is to motivate 
the scientific field to consider the concerns of the potential users of their techniques 
and thus, produce more acceptable and comfortable clinical methods and therapies. 
This then has the potential to greatly increase the accessibility of clinical genetic 
editing, in terms of whether or not individuals will feel comfortable with their genetic 
editing techniques and consider it a viable option. I hope to show the benefits of this 
interdisciplinary approach and spark more discussions between the scientific and 
religious communities, that normally tend to be separate.  
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CHAPTER ONE. 
CHRISTIAN STANCES ON GENETIC EDITING:  
RESISTANCE AND OPENNESS 
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Introduction 
Sitting in the waiting rooms of obstetrics and gynecology medical facilities are 
countless individuals who are not only thinking about Pap smears, STI testing, 
fertility, pregnancy and birth control, but today have to think about questions 
regarding genetic testing and editing. With the rapid development of genetic 
technologies such as CRISPR-Cas9 genome editing, the genetic editing of embryos 
is more realistic than ever before. These questions about genetic editing exist not 
only at OBGYN offices, but also in segments of life that pertain to one’s own life 
instead of future children. Genetic technology research ranges from the genetic 
editing of eggs and sperm to discovering the intricacies of cancer through genetic 
events (Sánchez-Rivera et al., 2014, p. 428). 
 The common misunderstanding of the Christian stance on genetic 
engineering is that the tradition simply does not agree with it; however, this quick 
assumption ignores the distinct complexities within Christian dialogue surrounding 
genetics and the possibilities for developing more acceptable forms of genetic 
engineering. Although there are similar Christian concepts used in arguments for 
and against genetic editing, the way they are used can contradict each other. These 
contradictions present within the discourse highlight tension zones within the 
Christian tradition which contain particularly complex or contradictory 
understandings. These zones can be utilized by scholars when developing novel 
avenues of future genetic research, as there are multiple Christian interpretations to 
possibly align with.  
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 I argue that the Christian discourse of genetic editing is rooted in four major 
concepts (the beginning of life, Creator-human relationship, imago Dei, and 
stewardship) and that although these concepts inform individual arguments, the 
defining factor between support and rejection is the perception of genetic editing in 
relation to harm; support of genetic editing is grounded in the categorization of 
genetic editing as a reduction of harm, while rejection is due to the categorization of 
it as inflicting harm. Two major concepts utilized by Christian arguments against 
genetic editing are the beginning of life and the Creator-human relationship. 
However amongst these, each argument has a uniquely nuanced understanding of 
the Christian concept. While still being informed by the Christian understanding of 
the beginning of life and Creator-human relationship, some arguments that support 
and reject genetic editing incorporate the concepts of imago Dei and stewardship. 
Although these two categories have arguments against genetic editing, here I also 
locate Christian support for genetic editing, which is a product of understanding 
genetic editing as reducing harm in some way rather than inflicting harm 
Because of the notion that the Christianity and genetic editing occupy 
completely separate spaces, there is a significant lack of communication between 
religious and scientific communities. This has led to misinformed preconceptions 
regarding both the mechanisms and opinions of genetic editing. Thus, genetic 
editing research has evolved in heavy isolation from religious communities, 
producing genetic technologies that are scientifically intuitive but not as widely 
accepted by the religious public. Genetic editing research is only beneficial if it can 
actually help people, which can only happen if the techniques are accessible to a 
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broad patient spectrum. This chapter’s work in identifying individual Christian 
arguments about genetic editing, locating the tension zones, and highlighting the 
defining harm factor between rejection and support of genetic editing, is important as 
it starts the journey towards producing genetic technologies that can possibly be 
more accepted by a religious public.   
 Thus in this chapter, I present individual Christian arguments for and against 
genetic editing. As mentioned, arguments about genetic editing make use of four 
major Christian tension zones: beginning of life, Creator-human relationship, imago 
Dei, and stewardship. The use of these concepts creates tension whereby the 
arguments utilize a general concept in contradictory or different ways. In what 
follows, the individual arguments are presented under the tension zone in which they 
fall. Their rejection or support of genetic editing is explained based on whether 
genetic editing is categorized as reducing or inflicting harm.  
Beginning of Life 
 Within the medical field there is a very present debate on what stage life 
begins: Is a zygote a bundle of cells or a unique life? Can a fetus or embryo be alive 
if it is not self-sustaining? Although this is a debated topic amongst medical 
professions, the conservative Christian understanding of the beginning of life is 
rather concrete: at the moment of conception. In its ethics statement, the Christian 
Medical & Dental Association writes that “the Bible states that human life begins at 
the absolute beginning or inception using the term ‘conception’”; and in order to 
clarify any confusion about the moment of conception, situates it as “the point of 
fertilization”. (Christian Medical & Dental Associations, 2006, p. 14). This 
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understanding is also at the root of the Catholic Church’s teachings on the care of 
human life, instructing a “protection of life in all its stages, from the first moment of 
conception until natural death” (Benagiano & Mori, 2007, p. 162). The Christian 
understanding of the beginning of life is specifically relevant to the topic of genetic 
editing, as it informs the majority of Christian arguments rejecting and supporting 
genetic editing. This section will analyze how two arguments utilize the Christian 
beginning of life as the primary reasoning for the rejection of genetic editing.  
Within the Christian discourse of genetic editing, arguments against the use 
of embryo-derived stem cells within genetics research heavily draw upon the 
understanding that life begins at conception. Stem cells are a unique type of cell that 
can “reproduce themselves, and can also generate daughter cells that become 
differentiated cells” (Slack, 2012, p. 3). These differentiated cells then come to form 
specified units of cells that develop into different parts of the body. Stem cells are 
particularly useful within genetics as they provide a “self-renewing population of cells 
and thus may reduce or eliminate the need for repeated administrations of the gene 
therapy” (U.S. Department of Health & Human Services, 2001). If a gene is modified 
within a stem cell, the subsequent cells and body units that are derived from that 
initial cell will also carry that modification; this mechanism is the basis of the 
administrative and research benefit of stem cells in genetics. There are two major 
categories of stem cells: adult and embryonic. Although stem cells can be derived 
from both sources, there are two major benefits of using embryonic stem cells: they 
are easier to extract and culture; and they are able to differentiate into a more a 
variety of cell types. One major Christian argument against stem cell usage within 
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research is that it would entail the “death” of a fetus or embryo; this argument fails to 
incorporate adult-stem cells that are not embryo-derived. Rooted in the Christian 
notion of the beginning of life, the U.S. Conference of Catholic Bishops states that 
“every living member of the human species, including the human embryo, must be 
treated with the respect due to a human person” (U.S. Conference of Catholic 
Bishops, 2004). Under this model, any use of stem cells “wraps the user in a state of 
complicit guilt, because the only way the stem cells could be used is at the earlier 
expense of an embryo or fetus” (Modell, 2007, p. 173). This rejection of genetic 
editing techniques due to its usage of stem cells is grounded in the specific Christian 
understanding of the beginning of life being at the moment of conception, which then 
categorizes an embryo as living and embryo-derived stem cell techniques as “killing” 
lives.  
While still utilizing reasoning rooted in the Christian beliefs about the 
beginning of life, some arguments against genetic technologies include the conjugal 
act as a necessary precursor for the creation of life. According to the Vatican, the 
conjugal act is established by God and serves both as unitive for the married couple 
and procreative (Pope Benedict XVI, 2006). In a letter addressing scientific 
advancements, the Vatican International Theological Commissions writes that “if a 
technique is used that does not assist the conjugal act in attaining its goal, but 
replaces it, and the conception is then effected through the intervention of a third 
party, then the child does not originate from the conjugal act which is the authentic 
expression of the mutual gift of the parents” (Vatican International Theological 
Commission, 2004). Here, the Vatican is addressing a specific scientific 
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advancement used within genetics, in vitro fertilization (IVF). IVF is clinically used as 
a reproductive technology that fertilizes a mature egg with sperm outside of the body 
and in a lab. This now fertilized egg is then implanted in the female’s uterus in hopes 
of maturing into an embryo (Sher, Davis, & Stoess, 2005, p. 64). This technology is 
useful for genetic techniques as it can be used in order to easily modify the genes of 
the, sperm, egg, and fertilized egg. IVF is currently not compatible with Vatican’s 
necessity of the conjugal act in the beginning of new life, as it circumvents any 
necessary physical sexual intercourse between the married couple. Thus, the 
Vatican frames one of its arguments against genetic editing in its usage of IVF and 
the creation of life without the God ordained conjugal act.  
Within the Christian discussion of genetic editing, many religiously based 
arguments draw from the Christian understanding of the beginning of life at the 
moment of conception and induced by conjugal act; although these arguments are 
building upon the same general concept, they are calling into action different 
components of the beginning of life. This complexity in Christian reasoning allows for 
those within the tradition to align or disagree with any one of the many varieties 
within the discourse, while still overall holding a Christian stance on genetic editing. 
This complexity within elements of the Christian beginning of life still lead to a 
rejection of genetic editing, however. An understanding of these objections can be 
important for future genetics researchers to keep in mind as they research new 
genetic technologies and mechanisms.  
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Creator and Human Relationship 
The perception of what being a human entails can vary from community to 
community. The Christian understanding of the elements of being a human is deeply 
attached to the understanding of God. Within the Christian tradition and specifically 
in the two creation story accounts of the Bible, God is defined as the Creator and the 
rest is God’s creation. In these accounts, the God’s creations are never said to 
independently create any other creatures. This characteristic Creator-human 
relationship has a stark divide between the two and allows little to none movement 
between the two roles. This firm relationship is relevant to this study of genetic 
editing debates, as it can serve as a basis to guide individuals’ judgements of 
genetic editing based on whether it is compatible with the human’s role or if it tries to 
“play” Creator. In order to understand how the Christian Creator-human relationship 
is utilized within the discourse, two major arguments will be analyzed within this 
subsection: Agneta Sutton’s and Mathias Beck’s rejections of genetic editing.  
One major argument that utilizes the Christian understanding of the Creator-
human relationship is Sutton’s rejection of the use of genetic germline editing. 
Germline cells, such as eggs or sperm, are those cells whose genes are heritable 
and transmitted to an offspring. On the other hand, somatic cells are not heritable 
cells and can be found in the other various other parts of the body. Thus, germline 
genetic editing affects the future progeny. In her argument, Sutton addresses 
parents as her audience and urges them to reject germline genetic editing, as it both 
oversteps the Christian human role and fails to respect children as a gift from God. 
Sutton’s understanding of the Christian hierarchical relationship is that humans do 
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not have the right or power to alter themselves and their lives; Sutton writes that 
“there are both physical and moral limits to our powers. As Christians we recognize 
that our lives are in God’s hands and that ultimately we cannot save ourselves or 
others” (Sutton, 2012, p.153). Sutton expands on this understanding of God’s power 
and the human lack of power when writing,   
Accepting children as gifts means not making their welcome depend on 
whether they satisfy standards set by us of health, ability, or beauty. At issue 
are human attitudes and aspirations that undermine the welcome of the child 
as a gift and deny it the respect it deserves as another person whose life 
comes to us as a gift from God. (Sutton, 2012, p.149) 
For Sutton, children are gifts from God and creatures whose components are all God 
ordained and thus off-limits to human controlled modification. Any modification of 
them is considered a failure to unconditionally welcome God’s gift and ultimately a 
form of harming this life.  Using this understanding, any form of germline genetic 
editing is seen as a clear disrespecting and harming of God’s creation, God’s gift to 
humans. In this argument Sutton is specifically addressing parents and therefore 
only addresses germline genetic editing as it is extremely applicable to reproductive 
decisions. However, based on the understanding of the Creator-human roles used in 
this argument, God as the Creator and humans as gifts from God, it seems that 
Sutton would also oppose all genetic editing because any modification would be in 
fact modifying God’s gift. Thus, Sutton utilizes an understanding of the distinct roles 
of God and humans and an understanding of modification as harm to support a 
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rejection of genetic editing should. For Sutton, genetic editing is both an attempt of 
humans overstepping the Creator-human divide and a mistreatment of God’s gift.  
 Looking at the creator-human relationship from another angle, Matthias Beck 
also positions the God-human relationship at the forefront of the rejection of genetic 
editing. Beck works within an epigenetic framework. Epigenetics is a relatively new 
sub-field of genetics that explores how environmental conditions can affect and 
change “gene activity without changing the DNA sequence” and can lead to 
“modifications that can be transmitted to daughter cells”(Weinhold, 2006, p. A163). 
These environmental conditions are commonly referred to as drivers or agents. 
Beck’s explains his understanding of epigenetics when he writes,  
Bodily relation-events reach down to genetic linkages. Genes are not merely 
present, in their damaged or healthy form, but they interact, and they can be 
switched on or off. Only switched-on genes are effective. The mechanisms for 
such switching are only partially known so far. But it seems that the brain, and 
thus a person’s thinking and feeling, is involved in them. (Beck, 2007, p. 79) 
Although there are scientific studies that link traumatic emotional events to 
epigenetic modifications, Beck’s description misrepresents this modification as 
something that a person can easily turn off/on just by thinking. Current findings in 
epigenetics identify possible drivers as: “heavy metals, pesticides, diesel exhaust, 
tobacco smoke, polycyclic aromatic hydrocarbons, hormones, radioactivity, viruses, 
bacteria, and basic nutrients”; these drivers and their epigenetic effects have been 
linked to a variety of illness and health indicators such as “cancers of almost all 
types, cognitive dysfunction, and respiratory, cardiovascular, reproductive, 
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autoimmune, and neurobehavioral illnesses” (Weinhold, 2006, p. A160). Although 
this is the scientific explanation of epigenetics, Beck describes epigenetic 
mechanisms when stating, 
Many diseases have genetic backgrounds. Defective genes, however, do not 
necessarily lead to subsequent illness. Genes have to be switched on or off. 
Only activated genes trigger pathological change. The human brain and all of 
man’s thinking and feeling are intimately connected with such activations. We 
may thus conclude that both inner life and religious outlook on life are 
relevant to the origin and development of diseases. (Beck, 2007, p. 67) 
Beck’s understanding of the Creator-human relationship fuels his claim that 
epigenetic drivers are in direct derivatives of an individual’s relationship with God 
and that this relationship is what dictates whether God “switches” the genes on or 
off. Therefore, the human modification of genes would not be effective in actually 
reaching a desired outcome, because God has the “real” power over genetic 
activation. Under this model, genetic editing as a way of medical therapy for 
diseases is not targeting the true source and therefore not reducing any harm to life. 
Instead, Beck is arguing for individuals to spend their time investing in their 
relationships with God, as that is the initial cause; God has the power to then turn on 
or off the selected genes.  
 The Christian understanding of the Creator-human relationship utilized in both 
Sutton’s and Beck’s arguments describe a firm hierarchal divided relationship 
between humans and God; God has the control over the creation and the creation 
do not have control to modify themselves. Sutton adds a complexity to this 
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understanding by claiming that humans are not only creations but also gifts from 
God that are warranted an unconditional welcome into the world. This then positions 
genetic editing as both a breach of the Creator-human divide but also as a 
mistreatment and harm of the lives of God’s creation. Beck includes an epigenetic 
element to the Creator-human relationship that explains epigenetic events as direct 
products of a stressed Creator-human relationship. Genetic editing is then 
understood as an ineffective approach to reducing any harm caused by genetic 
conditions; instead, Beck advocates for individuals to fix their relationships with God 
which will then allow for the possibility of God turning on or off particular genes. 
Even though both arguments each employ elements of the Creator-human 
relationship as evidence for the rejection of genetic editing, there is diversity in what 
sub-elements regarding the reduction or accretion of harm are utilized.  
Imago Dei 
 In the Christian tradition not only do the concepts of the beginning of life and 
the Creator-human relationship guide individuals’ judgements of genetic editing, but 
also the Christian concept of imago Dei (“image of God”) plays a major role in the 
Christian rejection and support of genetic editing. A common biblical verse that 
informs the community of imago Dei is Genesis 1:27, “So God created man in His 
own image, in the image of God He created him; male and female He created them” 
(New International Version). Imago Dei informs the Christian understanding of the 
nature of human creation and identity as direct expressions of God. This concept 
manifests itself in Christian life as it expresses a “foundational relationship between 
God and man, with implications for properly appreciating basic human goods and 
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human flourishing, which in turn have repercussions for medical decision-making” 
(Cherry, 2017, p.219). Specifically, imago Dei is used within the Christian discourse 
of genetic editing in three major ways: imago Dei as a necessary understanding that 
prevents development of immoral reproductive ethos; imago Dei as the basis of the 
categorization of genetic editing as a mistreatment of a gift that is made in the image 
of God; imago Dei as the reasoning behind a support of genetic editing as a means 
to help individuals express their true identity.  
When addressing a wide range of reproductive medicine that includes 
prenatal genetic testing, in vitro fertilization, and abortion, some arguments rely on 
imago Dei as a necessity that prevents individuals from developing a misinformed 
stance on reproductive issues. Associate Senior Editor of Christian Bioethics, Mark 
Cherry expresses the importance of imago Dei, when writing “Reference to the 
Imago Dei expresses a foundational relationship between God and man, with 
implications for properly appreciating basic human goods and human flourishing, 
which in turn have repercussions for appropriate medical decision-making” (Cherry, 
2017, p.219). He later claims that when the Christian or general body forgets that all 
humans are made in the image of God, an ethical reproductive ethos forms that 
“normalizes not only contraception to control when to have children and medical 
selection of embryos for desirable traits through assisted reproductive technology, 
but also prenatal diagnosis and selective killing in utero of children with a likelihood 
of disabilities or undesirable genetic characteristics” (Cherry, 2017, p.224). This 
argument utilizes not only imago Dei, but also the Christian understanding of the 
beginning of life at conception. For Cherry, imago Dei is a necessary concept to 
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integrate into one’s own moral judgement that leads to the development of morally 
sound medical decisions. Also, imago Dei manifests in Cherry’s rejection of any 
categorization of desirable and undesirable traits. For Cherry, all elements of an 
individual, whether desirable or not, are representations of God. The understanding 
of the beginning of life informs Cherry’s rejection of prenatal diagnosis that can lead 
to abortions and family planning methods that he understands to be selecting a 
promising embryo and “killing” the others. The blending of the two elements, 
beginning of life and imago Dei, continues within Cherry’s rhetoric and specific 
usage of “children” instead of fetus or embryo. Cherry disapproves of individuals 
judging characteristics as desirable or undesirable, because each and every 
characteristic is made in the image of God. Here we can see Cherry’s understanding 
of embryos and fetuses as already independent lives and souls and the removal of 
them as “killing”. Cherry’s disapproval of genetic editing is based both in the 
Christian understanding of the beginning of life and imago Dei and Cherry’s 
understanding of genetic editing and possible endings of pregnancies as inflicting 
harm on these lives.  
 In a letter commenting on current scientific advancements, the Vatican 
International Theological Commission addresses genetic technologies and 
specifically the genetic editing of humans. Here the Vatican relies heavily on the 
concept of imago Dei as the essential nature of humans to inform a rejection of 
genetic editing based on a failure to value that human qualities are all made in the 
image of God. In this letter the Vatican positions imago Dei as the center piece for its 
framework and explains it as the key to a biblical understanding of “human nature 
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and [key] to all the affirmations of biblical anthropology in both the Old and New 
Testaments. For the Bible, the imago Dei constitutes almost a definition of man: the 
mystery of man cannot be grasped apart from the mystery of God” (Vatican 
International Theological Commission, 2004). For the Vatican, this defining 
characteristic of humans informs its opinion against the genetic editing of humans 
and is further explained when the Vatican writes, “A right to dispose of something 
extends only to objects with a merely instrumental value, but not to objects which are 
good in themselves, i.e., ends in themselves. The human person, being created in 
the image of God, is himself such a good” (Vatican International Theological 
Commission, 2004). Imago Dei is an element of being human that sets humans 
aside from other objects on earth. The Vatican’s rejection of genetic editing is 
founded in the concept of imago Dei which informs the conclusion that human 
genetic modification would be an infliction of harm as it would be changing 
intrinsically good characteristics. 
On the other hand, the notion of the full expression of an identity that is made 
in the image of God is utilized in support of genetic editing. Although contradictory to 
the Vatican’s previous rejection of genetic editing, within the same letter the Vatican 
advocates for an acceptance of genetic editing as a method to help people fully 
express their identity which may be obstructed by congenital diseases. The 
Vatican’s very clear supportive stance on the genetic editing of congenital diseases 
stands out against the many Christian campaigns against finding a Down Syndrome 
“cure” (Curtis, 2011;)Knight, 2017;)Peoples, 2017). In this letter the Vatican claims 
that congenital diseases such as Down Syndrome negatively affect the identity of a 
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person both physically and mentally. Thus, the Vatican advocates for genetically 
altering these conditions as the modification would “help the individual to give full 
expression to his real identity which is blocked by a defective gene” (Vatican 
International Theological Commission, 2004). This particular framework positions 
Down Syndrome and similar genetic conditions as barriers that constrict the ability to 
fully express a person’s God given identity. In this scenario, genetic editing acts as a 
mechanism to remove the “defective gene” and therefore, reduce the harm caused 
by the disease preventing a God-given right to a full expression of identity. Although 
this is contradictory to other statements given by the Vatican, this support of the 
genetic editing of congenital diseases highlights the possibility of the Christian 
support of genetic editing when it is understood as a reduction of harm. 
  The concept of imago Dei is a major factor in many Christian arguments 
about genetic technologies, however the arguments each utilize different details of 
imago Dei to support or reject genetic editing. Cherry’s argument centers in on the 
concept of humans being made in the image of God; in his view, forgetting this 
essential truth leads to the development of morally corrupt stances on reproduction. 
These stances would then lead to medical decisions that Cherry believes are 
harmful to current and future lives such as abortion and editing undesirable genetic 
characteristics. The Vatican’s anti-genetic editing argument addresses genetic 
editing by specifying that changing an essential part of a human ceases to 
acknowledge the holy nature of humans being made in the image of God and would 
thus be inflicting harm on the individual. The Vatican’s pro-genetic editing argument 
positions congenital diseases as barriers to a full expression of an imago Dei identity 
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and genetic editing as a mechanism to help reduce the harm cause by those 
diseases and allow full expression of identity. Although all three arguments 
incorporate the concept of imago Dei, their rejection or support of genetic editing is 
due to how imago Dei informs their judgement on what exactly is inflicting or 
reducing harm. For example, a condition may be considered to inflict harm on an 
individual if they understand this condition to be preventing the individual from fully 
living out their true identity. However, if the individual understands all characteristics 
as being made in the image of God, then any modification of that condition could be 
considered a disrespect or mistreatment of something truly imago Dei. 
Stewardship  
Within the Christian understanding of the hierarchal Creator-creation 
relationship, humans are entrusted with the responsibility to be stewards. This role 
and its application in today’s scientifically advanced world has allowed for more 
variety of stances on genetic editing. Two common biblical passages that inform the 
Christian tradition on stewardship are Luke 12:41-48 and Matthew 25:14-30. The 
Luke parable informs on how to be a good steward through an analogy of a master’s 
manager in charge of his servants and how to care for them. The passage from 
Matthew is the parable of the Bags of Gold in which a master gives his servants 
bags of gold in which the good and faithful servant invested his money so that when 
the master came back to collect the gold he gave more than was initially allotted to 
him. However, the “lazy servant” hid the money in a hole so that when the master 
came back he only gave back the same amount initially given to him. Both of these 
stories provide messages of taking care of God’s creations and of cultivating God’s 
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gifts so they are more abundant in the future. In a letter from the United States 
Conference of Bishops on how to be a Christian steward, stewardship is explained 
as “respect for human life—shielding life from threat and assault, doing everything 
that can be done to enhance this gift and make life flourish” (United States 
Conference of Catholic Bishops, 2006, p. 451). This understanding of stewardship 
within the greater Creator-human relationship is relevant to Christian genetic editing 
discourse, as it can influence individuals’ judgements on genetic editing and whether 
or not it is proper care of God’s creation. This section will analyze three different 
Christian arguments about genetic editing that utilize stewardship in their claims that 
genetic editing either harms individuals and is therefore not proper stewardship or 
helps protect and enhance individuals and is therefore appropriate stewardship.  
The use of stem cells within genetic research and clinical applications of 
genetic technologies is a Christian moral dilemma that calls into question whether 
humans are fulfilling the role of stewardship. Public Health scholar Stephen Modell 
attempts to situate genetic editing within the Christian understanding of stewardship 
in regard to its usage of stem cells. Modell understands the acquisition of stem cells 
to be from either germline cells of aborted fetuses or fertilized eggs not used during 
in vitro fertilization and considers both methods as including the “death” of a fetus or 
embryo. The choice to use the word “death” when describing the termination of 
fertilized eggs exemplifies elements of the Christian understanding of the beginning 
of life fueling the argument; for Modell the fertilized egg, embryo and fetus are all 
alive. Thus he claims that “downstream use of stem cells wraps the user in a state of 
complicit guilt, because the only way the stem cells could be used is at the earlier 
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expense of an embryo or fetus” (Modell, 2007, p. 174). For Modell, any use of stem 
cells is intimately connected to the death and harm of lives. Since genetic 
technologies can rely on stem cells for their research, the clinical use of genetic 
editing cannot be separated from its harm to lives; thus, positioning it as counter to 
the stewardship role awarded to Christians.  
Within the discussion of whether current genetic technologies fulfill or oppose 
the Christian call to stewardship, the care of not only the current and immediate next 
generation but all future progeny are included. Philosophy and Biomedical Ethics 
scholar James Delaney explains the Catholic Church’s position on genetic 
engineering when writing that the Catholic Church distinguishes “between somatic 
cell therapy and germ line cell therapy, and prohibits the latter, because of two 
reasons: its potential to harm progeny and its use is in conjunction with in vitro 
fertilization” (Delaney, 2009, p.33). Although this may seem like a rejection of 
genetic technology as we currently know it, Delaney goes on to describe the very 
concrete changes within genetics that would allow for Catholic approval: 
Should the current state change in the following two respects, 1) risks to 
progeny are reduced so as to be out- weighed by likely therapeutic benefits, 
and 2) the subjects involved in the germ line therapy (either gametes or early 
stage embryos) do not affect persons coming into existence through a morally 
licit act (the conjugal act between a husband and wife), the Church’s position 
on germ line therapy would likely be that it is morally permissible. (Delaney, 
2009, p.33) 
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Delaney applies the call to stewardship to all current and future progeny by arguing 
that when the benefits of genetic editing outweigh the risks to currently non-existing 
lives, then germline genetic editing will be closer to being accepted by the Catholic 
Church. In addition, elements of the Christian understanding of the beginning of life 
complicate the Catholic Church’s position on genetic editing. It seems that for 
Delaney embryos or fetuses not formed through conjugal act, such as through in 
vitro fertilization, are in fact not considered alive; this understanding is drawn from 
Delaney’s second condition about persons coming into existence through a morally 
licit act. Therefore, the use of them can possibly be warranted because there is 
technically not harming of life. Throughout the article Delaney continuously critiques 
germline editing, which hints at Delaney not rejecting somatic gene editing as it 
would not entail the death of embryos or harm to future progeny. The current 
rejection of existing mainstream genetic technologies and the presentation of 
qualifications for potential acceptance of future genetic technologies both utilize the 
potential harm of progeny and harm of current lives as major factors for evaluation; 
thus, potential harm of progeny and embryos/fetuses should not be considered a 
“dead end” for genetic advancements but rather considered an avenue for potential 
acceptance.   
Although stewardship has been used as criteria for the rejection of genetic 
editing and the proposal of changes to current methodologies, it can also be used as 
a framework to advocate for the usage of genetic editing. Rooted within a Christian 
pro-life framework, political scientist and biologist Brendan Foht focuses on the 
stewardship of fetuses and advocates for the usage of genetic editing as it can 
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increase the chances of survival for a fetus. Foht positions the analysis of genetic 
editing in contrast to abortions that are informed by prenatal screenings when 
writing, “Morally speaking, editing the genes of embryos rather than destroying them 
would be a step in the right direction” (Foht, 2016, p. 12). Foht considers genetic 
editing as a preferable alternative to the abortion of fetuses with unwanted 
characteristics. Here elements of the Christian concept of the beginning of life inform 
Foht’s understanding that embryos are in fact alive and the termination of them is 
“killing”. In conjunction, Foht’s analysis of the harm in each case facilitates his 
approval of genetic editing as it would in actuality reduce the harm of a life that 
would have been ended otherwise.  
The Christian duty of stewardship is called upon throughout debates over the 
use of genetic technologies. Although God’s call for humans to be stewards is 
relatively agreed upon within communities, what exactly this stewardship calls for is 
not standardized. For Modell, stewardship, informed by the Christian understanding 
of the beginning of life, includes the protection of embryos and fetuses which allows 
for Modell to reject the use of genetic editing because it is a downstream use of stem 
cells and the “death” of embryos and fetuses. Delaney utilizes the concepts of the 
beginning of life with the conjugal act and stewardship when concluding the current 
germline genetic technologies both harm future progeny and utilizes “killed” embryos 
and fetuses; instead, Delaney proposes utilizing embryos not created via conjugal 
act and developing genetic technologies where the benefit will outweigh the risks of 
harm to future progeny.  Foht also applies stewardship to fetuses but concludes that 
genetic editing would technically be a form of care and reduction of harm if it 
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increases the chances of survival. Intricacies within Christian stewardship such as 
caring for potential progeny, embryos, and fetuses allow for both Christian 
acceptance and rejection of genetic technologies; however similar to previously 
identified trends, the understanding of genetic editing as potentially protecting or 
reducing the harm of lives allows for a Christian justification of genetic editing.  
Conclusion  
There is a common misunderstanding that a unanimous Christian rejection of 
genetic editing exists; instead, there is a medley of rejections and acceptances with 
contradictions that highlight four major tension zones: the beginning of life, the 
Creator-human relationship, imago Dei, and stewardship. Aside from which of these 
different Christian concepts are utilized, the arguments within the Christian genetic 
editing discourse differ from each other depending on the understanding of genetic 
editing in regards to harm. All of the arguments that understood genetic editing to be 
inducing harm rejected genetic editing, while the arguments that supported genetic 
editing understood it to be a form of reducing harm. This judgement-call on whether 
or not genetic editing is causing or reducing harm is rooted in the individual’s 
categorization of the genetic condition as being imago Dei or a barrier from fully 
expressing one’s imago Dei potential. A combined understanding of what the tension 
zones are and the determining harm factor is extremely important for geneticists, as 
it can help them identify possible avenues to explore and then develop genetic 
technologies that may be accepted and used by more individuals. With this chapter 
locating the tension zones and harm factor amongst the current Christian discourse, 
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these tension zones will be analyzed for how they can specifically be useful in the 
development of new genetic technologies.  
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CHAPTER TWO. 
FRUITFUL GENETIC EDITING RESEARCH PATHS 
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Introduction 
 A Christian married couple has been trying to have a child and participate in 
the Christian creation of life, however they were told by their physician that both of 
them are carriers of a congenital lethal disease. The couple is confused because 
they would still like to fulfill their marital calling to procreate but also fulfill their call to 
stewardship and care for their child’s health, protect them from a lethal disease that 
could potentially kill them. One of the most common paths couples could chose is in 
vitro fertilization (IVF), which fertilizes a couple egg samples with sperm in petri dish 
and after enough division cycles, the healthiest or in this case the one without the 
disease gene is selected and the rest are discarded. However, this would not be a 
possible path for this couple as it would involve the ending of a life under a particular 
Christian definition (fertilized egg) and it would omit the conjugal act, also central to 
some Christian understandings of the production of life. Genetic editing is a potential 
path that the couple could consider as a way to possibly secure that their future 
progeny would not suffer from this condition. Genetic editing is the modification of an 
individual’s genetic information (DNA) in efforts to modify a genetic characteristic or 
trait of theirs. Although genetic editing of humans is a relatively novel study, there 
have been recent major strides in the research of clinical application of genetic 
editing of human embryos. For example, in 2017 embryologist Shoukhrat Mitalipov 
successfully modified a human embryo that originally carried a heart defect gene 
(Ma et al., 2017). Mitalipov’s team claims that this is a potential mechanism that 
would help “rescue mutated embryos that would otherwise be screened out of in 
vitro fertilization (IVF) procedures” (Servick, 2017). However, this specific method 
		 33	
would still not accomplish the Christian goal of ensuring the conjugal act in the 
creation of life. Within the Christian discourse of genetic editing, there is a concern 
regarding the necessity of the conjugal act as a mandatory precursor to the creation 
of life. As identified in the previous chapter, the Vatican claims that the conjugal act 
must not be replaced by but aided by reproductive technological techniques (Vatican 
International Theological Commission, 2004).  The inclusion or reliance on the 
conjugal act within genetic editing research poses to hurdles. It does indeed 
complicate the experimental logistics when transitioning to human subjects, 
compared to simply mixing sperm and eggs in a petri dish. Secondly, scientists tend 
to look at efficiency and reliability when proposing new clinical methods; relying on 
the conjugal act is not seen as the most direct path. Thus, there exists a scientific 
need to fulfill a deficit within the research community that lacks major consideration 
of possible techniques that include the conjugal act. Research in these areas that 
would prove useful to and accepted by many individuals would include epigenetics, 
somatic cell genetic editing, and in vivo genetic editing research.  
Epigenetics 
As previously explained in the last chapter, the Christian concept of 
stewardship, which calls for individuals to take care of and nurture God’s creation, 
fuels a call to protect current and future progeny from harm. Attending to the 
Christian concern about harm to progeny and the Christian calling of stewardship, 
Epigenetics is a specific field of genetics that focuses on hereditary gene functions 
that are not rooted in DNA sequence alterations; in other words, it focuses on 
structural changes that may affect the cell’s access to DNA via physical markers 
		 34	
such as the extent of tight coiling of the genetic material. In a 2008 epigenetics 
conference, an epigenetic trait was defined as “a stably heritable phenotype 
resulting from changes in a chromosome without alterations in the DNA sequence” 
(Berger, Kouzarides, Shiekhattar, & Shilatifard, 2009, p. 781). These epigenetic 
states of the genome can affect the accessibility of the genome and its expression. 
The three major epigenetic modifications are DNA methylation, histone modification 
and non-coding RNA- associated gene silencing. It is commonly understood that 
possible sources of epigenetic modifications can include one’s environment and diet. 
With epigenetics as a “buzz” field surfacing on the pages of multiple health blogs to 
scholarly scientific conferences, epigenetics has been incorporated into a diverse 
public discourse; it complicates the general understanding of hereditable information 
as predetermined and not affected by one’s own life. Although not the explanation 
for many genetic conditions, the epigenetic explanation of many gene expression 
conditions produces a sense of controllability regarding genetic conditions. Not only 
can lifestyle factors negatively affect gene expression, but certain lifestyle changes 
can instead benefit genetic expression and serve as epigenetic therapy that is not 
affecting the DNA itself. This ability to possibly “fix” one’s condition without having to 
physically change the DNA can facilitate individuals to feel more autonomous and 
capable of independently helping their condition and possibly no longer passing on a 
negative epigenetic marker onto their progeny.  
To investigate common lifestyle variables and their possible epigenetic 
effects, studies have investigated both environmental and dietary variables. 
Regarding the environment, pollution is a major concern as an epigenetic 
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modification initiator of histone acetylation. Dinga R et. al investigated this 
relationship between pollution and histone acetylation in mice model and claims that 
it can be used to help further elucidate the relationship between air pollutants and 
lung disorders (Ding et al., 2016, p. 170). Pertaining to diet, a recent study 
concluded that a ketogenic diet can help alleviate the a deficiency of chromatin 
opening common in Kabuki syndrome (Benjamin et al., 2017). Here, diet is used as 
a form of epigenetic therapy to help reduce the existing epigenetic condition of the 
genome in mice with Kabuki syndrome. A research group focusing on acute myeloid 
leukemia (AML), has identified epigenetic mutations that result in a pre-leukemic cell 
state (Wouters & Delwel, 2016). These researchers then identified that epigenetic 
therapy to this pre-cancerous state could help reduce the cases of this disease. 
These studies are all pre-clinical and producing vital information for future clinical 
epigenetic therapy. Current human epigenetic clinical trials include the development 
of histone deacetylase (HDAC) inhibitors for cancer therapy and neurological 
disorder treatment (Marks & Xu, 2009)(Kazantsev & Thompson, 2008). These 
inhibitors affect the chromatin packaging and expression of genes in charge of cell 
cycle events that are usually abnormally regulated in cancer cells (J. M. Wagner, 
Hackanson, Lübbert, & Jung, 2010).  
Although these clinical and pre-clinical trials show very promising results for 
the efficiency of epigenetic therapy, the easy reversibility of epigenetic changes 
lends itself to both the risk and benefit of the clinical use epigenetics as therapy. If 
an unintended epigenetic modification does occur during a treatment, it is very 
possible that it could be easily reversed. However, the opposite case of an 
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epigenetic beneficial modification being reversed could be considered a risk. Is the 
efficiency of epigenetic therapies reduced because of this reversibility and how long 
would therapy effects last? 
In regards to the specific Christian understanding and moral decision about 
epigenetics, very few have published any specific opinions on it. As noted in chapter 
1, one published Christian understanding of epigenetics understands the epigenetics 
markers as heritable effects of sin that can act as pre-dispositions to sin for future 
individuals (Beck, 2007). Due to the overall lack of published Christian arguments 
about epigenetics, I will focus on how epigenetic research and therapy might interact 
with the existing Christian themes and concerns of stewardship and prevention of 
harm.  
With its ability to help treat potential hereditary health complications and since 
epigenetic modifications are technically not changing the DNA material itself, 
epigenetic therapy appeals to the Christian theme of stewardship and concern about 
harm to progeny. Epigenetic therapy would allow individuals to remove/reverse 
harmful epigenetic markers from their genetic material without actually changing the 
DNA and thus without overstepping the Creator-human boundary.  Such treatment 
would allow Christian individuals to “take care” of their future progeny and thus be 
stewards of God’s gifts.  In addition to helping fulfill the Christian concern regarding 
the care and prevention of harm to future progeny, epigenetic therapy would address 
the Christian understanding of genetic conditions, discussed in the previous chapter, 
as linked to environmental stressors that are in fact resultant from the individual’s 
relationship with God (Beck, 2007, p. 67). In this case epigenetic therapy would be 
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addressing a physical component of a person’s hereditary material, but would still 
appeal to Christian epigenetic and environmental understanding of certain conditions 
rather than purely DNA based.   
Although there is an abundant amount of epigenetic research already being 
conducted and in the pipeline, an interesting epigenetic variable that would be 
important to understand more comprehensively through more research is the 
longevity of certain epigenetic mutations. This understanding of how long epigenetic 
modifications last before being reversed or even turned into something else can be 
important in deciding whether or not epigenetic therapy is clinically worthwhile.  
Somatic gene editing 
Another potentially productive genetic editing avenue to research is somatic 
gene editing, which appeals to the Christian stewardship call to prevent harm to 
progeny. As discussed in the previous chapter, somatic cells differ from germline 
cells in regards to heritability; somatic cells are not heritable and comprise the far 
majority of an organism. In theory, the modification of a somatic cell could affect a 
variety of somatic cells targeted but would not be transmitted to future offspring, as it 
would not be modifying any germline cells. In this section I will look at both current 
practices of fetal and adult somatic cell editing, the risks involved, and how they can 
alleviate some Christian concerns.  
Fetal somatic cell editing is an in utero method and has been identified as a 
potential “prenatal prevention and permanent correction of disease manifestation 
particularly for early onset diseases” (Coutelle & Rodeck, 2002, p.670).  Coutelle 
and Rodeck both identify in utero fetal somatic gene therapy as not only an excellent 
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preventative medicine option, but also an excellent option for individuals who find 
themselves having to consider pregnancy termination following the diagnosis of a 
severe genetic disease. The option of in utero fetal somatic gene therapy would 
allow them to instead edit this unwanted and harmful genetic disease, while still 
allowing them to keep the same fetus alive and not have as much of a pressure to 
consider abortion. Douar et al. investigated and solidified the role fetal somatic gene 
therapy can have in the prevention of irreversible perinatal diseases (Douar, Themis, 
& Coutelle, 1996, p. 633).  
A more recent study investigated easier ways to treat congenital 
diaphragmatic hernia, a condition that ultimately can hinder proper lung formation. 
Currently this disease is treated via a physically invasive endoscopy of the fetal 
trachea, which can be risky when done on delicate fetal membranes. Using the 
sheep as their model organism, the researchers concluded that sheep fetal trachea 
can be accessed and genetic therapy can be administered to it by vectors via 
percutaneous ultrasound-guided injections (David et al., 2003, p. 385). Basically, the 
researchers are proposing that an improved method to the fetal endoscopy would be 
to inject genetic editing material into the fetal trachea via a tiny needle and that the 
genetic editing material will be guided to the target area via specific wavelengths 
applied to the subject. This finding is exciting as it points to a near future where 
individuals will be able to “better protect” their progeny through genetic editing 
methods, as they could potentially be less prone to physical complications such as 
membrane rupture. In addition to research of fetal somatic gene editing, there has 
been lots of research in adult somatic gene editing.  
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Current research and clinical interest in adult somatic gene editing ranges 
from understanding the nature of cancer to metabolic diseases. In order to more 
comprehensively understand cancer, Sánchez-Rivera et al. performed a rapid 
modelling of cooperating genetic events in cancer through somatic gene editing 
(Sánchez-Rivera et al., 2014, p. 428). This modelling allowed them to better identify 
which mutations could be causing the tumorigenesis within a mouse model. In this 
study, the research team looked at common identified cancer-related genes within a 
lung-cancer model and systematically activated or deactivated them with genetic 
editing and observed its effect on tumorigenesis. The hope of this study is that a 
dense catalogue of cancer genome mutations can help identify early stages within 
the cancer timeline and subsequently be used to develop therapies for individuals 
(mostly non-fetus) with cancer. Since a majority of cancers develop later in life, the 
applications of this therapy would have more opportunities within adults rather than 
only simply in fetuses. In regards to somatic gene editing’s role in understanding 
metabolic diseases, it allows for an easier method of modeling. Currently 
researchers model metabolic diseases by genetically editing germline cells and 
breeding said cells to produce metabolically diseased model organisms. However, 
Jarrett et al. explored the possibility of using somatic editing to simply edit already 
existing adult individuals so that they express the desired mutation (Jarrett et al., 
2017, p. 1). This method allows for an easier research method that opens up paths 
towards more feasibly research of metabolic diseases and therapies.  
Somatic gene editing has clearly allowed for groundbreaking and helpful 
understandings of medical conditions and the nature of cells. The clinical use of 
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somatic gene editing allows for specific non-hereditary genetic editing that lacks the 
same risk to progeny that accompanies germline editing. However, this usage does 
come with some risks that are important to identify. First, although somatic gene 
editing in theory should not be transmittable to offspring, there is still an underlying 
risk of germline transmission. A research team from the Department of Obstetrics 
and Gynecology or Bern University Hospital, explains this risk as “Because vector 
integration into germ cells, if it occurs, is likely to be random, an integration event 
could potentially have disastrous effects for progeny conceived from such a germ 
cell” (A. M. Wagner, Schoeberlein, & Surbek, 2009). This same research team 
identifies another potential risk, maternal spread: “the possible risk of vector spread 
from the fetus to the maternal body, although the number of layers may not be the 
only factor determining placental permeability” (A. M. Wagner et al., 2009). Although 
current studies suggest this risk is relatively low, I agree with this research team in 
the necessity for more research in order to fully understand maternal cell 
transduction (Ye, Gao, Pabin, Raper, & Wilson, 1998). In my opinion, this potential 
risk to the mother seems like it would not sit well with the general and Christian 
population. However, when analyzing the Christian discourse of genetic editing, 
there are no major arguments pro or against genetic editing addressing risk to the 
mother. This then points to a seeming lack of attention towards women’s health in 
regards to genetic editing within the Christian discourse.  
In regards to the relationship between further development of somatic genetic 
editing and Christian discourse of genetic editing, somatic genetic editing could 
potentially help fulfill the Christian concerns regarding the safety of future progeny 
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and the need for the conjugal act in the creation of the new life. As highlighted in the 
previous chapter, the Catholic Church distinguishes “between somatic cell therapy 
and germ line cell therapy, and prohibits the latter, because of two reasons: its 
potential to harm progeny and its use is in conjunction with in vitro fertilization” 
(Delaney, 2009, p.33). In conjunction with the general understanding of a low 
germline transmission (Ye et al., 1998), somatic genetic editing allows for a safer 
method of treating genetic conditions without unforeseen future effects on offspring 
that are potentially possible in germline editing. With further research, adult somatic 
gene editing techniques could be developed that solidified the editing of cancerous 
tumors in adults via cancer cell targeted genetic editing materials, whether through 
ultrasound or other guiding mechanisms. In addition to appealing towards the 
Christian stewardship element of prevention of harm, somatic gene editing can 
appeal towards the Christian necessity of the conjugal act when procreating. The 
option of editing the somatic cells of a fetus, allows a Christian individual to both 
create life via the conjugal act but also, if the individual had been considering the 
pregnancy termination, this would allow another option that would be more accepted 
by the Christian public.  
In addition to appealing to Christian concerns, somatic genetic editing 
appeals to bioethical and general medicinal goals. First, the ability to genetically edit 
the somatic cells of individuals, and specifically adults, situates itself well within 
bioethical concerns about agency. With adult editing, there is clearly more agency 
provided towards the individuals, in contrast to genetically editing the somatic cells 
of fetuses. The somatic cell editing of fetuses, on the other hand, seems to address 
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the concerns of the medical goal of pushing towards a future of preventative 
medicine. In 2002, 8 major healthcare member organizations, ranging from doctors 
to pharmacists, collaborated to implement healthcare objectives titled the “Clinical 
Prevention and Population Health Curriculum Framework” as a major effort to help 
the United States healthcare system shift from one of diagnostics/curative to one of 
preventative(RK Riegelman & Garr, n.d.). Somatic cell editing appeals to this model 
of preventative medicine, as it allows for the treatment of potential at risk cells before 
a major disease develops. 
In regard to Christian, general medical, and bioethical concerns, further 
somatic genetic editing would prove productive in the development of more 
acceptable and therefore, usable forms of genetic editing. Further research into the 
amount of germline transmission present within somatic editing treatments would 
help elucidate the amount of potential harm to progeny there actually is; this can 
then increase the amount of information individuals have when deducing their 
potential medical paths when faced with genetic conditions. In addition, there must 
be further research into the potential maternal risk during fetal editing, both to 
increase the agency of the women undergoing this procedure but also to help further 
build a future within medical and Christian discourse that commonly incorporates 
women’s health and concerns.  
In vivo genetic editing 
Not only is the type of genetic information being edited important, but also the 
mechanism that it is accessed and edited is just as pertinent in regards to Christian 
acceptance. When it comes to the editing of progeny, whether before or after 
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conception, the method of fertilization utilized is important as there is a Christian 
need for to maintain a tradition understanding of conception through the marital 
conjugal act. The Christian pushback against some clinical fertilization techniques 
such as in vitro fertilization (IVF) are rooted in this exact concern that rejects the 
fertilization of the egg in a laboratory petri dish and advocates for the couple to 
instead procreate via heterosexual intercourse. This is relevant to this discussion of 
genetic editing as scientific and specifically genetic studies are commonly one of 
three types: in vivo, in vitro, and in silico. In vivo experiments are carried out within a 
living organism and is capable of producing a greater understanding of the total 
effects of a variable on the entire organism, including its total interaction with other 
body variables. In vitro experiments are the opposite of in vivo and are not 
conducted within a living organism. These studies produce a less comprehensive 
understanding of the particular independent variable’s effect as it does not 
incorporate organismal conditions as well as in vivo studies. However, in vitro 
studies benefit from not having as much of a risk of harming actual organisms and 
are more easily reproducible. In vitro techniques are common amongst reproductive 
scientist in regards to egg/sperm extraction and in vitro fertilization, because it can 
provide a sterile, easily observable and controllable environment. In silico refers to 
studies performed using a computer software simulation and an abundant database. 
This is a relatively newer form of experiment that is commonly used as a primary 
investigation of a variable or mechanism and can help construct possible in vivo or in 
vitro studies of the same variable. In genetics, in silico studies are now ever present 
in gene expression analysis(Murray, Doran, MacMathuna, & Moss, 2007). With this 
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background of current experimental approaches, this section focusses on in vivo 
genetic editing of eggs (fertilized and non-fertilized) and sperm and analyzes it as a 
potential productive avenue of clinical genetic editing that will be more accepted by 
Christian users by appealing to the inclusion of the conjugal act.  
Although not currently clinically used, in vivo genetic editing locates itself in a 
variety of contemporary research studies. What does this current in vivo genetic 
research look like? In 2015, Lukas Dow et al. published a study that examined 
inducible in vivo genome editing with CRISPR-Cas9 in mice and claims that an 
“inducible CRISPR (iCRISPR) system can be used effectively to create biallelic 
mutation in multiple target loci and, thus, provides a flexible and fast platform to 
study loss-of-function phenotypes in vivo”(Dow et al., 2015, p. 390). Dow’s team 
essentially provides a viable approach to rapid and scalable studying of gene 
functions in vivo. Also using mice as their model organism, in 2011 Hojun Li et al. 
study how in vivo genome editing can restore hemostasis, the stopping of bleeding, 
in hemophilia, a genetic disorder that reduces an organism’s ability to form blood 
clots and terminate bleeding. Before this study, the use of zinc finger nucleases 
(ZFNs) was used in genome editing in vitro, however this research wanted to 
explore its efficiency in vivo. By examining the effective level of gene targeting and 
concluding that it could effectively correct the hemophilic prolonged blood clot times, 
they were able to claim that this “ZFN-driven gene correction can be achieved in 
vivo, raising the possibility of genome editing as a viable strategy for the treatment of 
genetic disease”(Li et al., 2011, p. 217). This research team’s finding show that ZFN 
can not only be used in vivo, but that it can efficiently bind the new desired gene to 
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the targeted location with the necessary consistency and efficiency to be a clinically 
viable method. With studies like the ones presented showing the viability and 
efficiency of in vivo genetic editing and the beneficial clinical applications, its future 
clinical use on humans is near and the risks of the clinical human application are 
important to consider.   
With in vivo genetic editing, there is an inherent risk that accompanies the 
therapy being done within the living organism. The off target of gene editing is a 
measurement of unwanted genetic manipulations of the genome. This means that 
possible unwanted mutations could include the wrong gene being edited or the 
wrong cell/tissue type being edited. In vivo, if there is a mistake and a different gene 
is modified or if the wrong cell type is edited, it can possibly affect multiple 
unintended regions of the body. For example, if one wanted to target a specific gene 
and there was another gene that had a similar coding region to the target, the editing 
mechanism has a risk of binding to the unintended region. This would then result in 
an unintended effect, commonly called the off-target effect. If an individual wanted to 
target a controlled section of the body such as the eggs but the mechanism used 
traveled to another region and edited that, there could potentially be unintended 
effects. In contrast, in vitro editing mistakes could not travel to and affect other 
regions and these mistakes could be easily identified and those affected cells could 
simply not be used.   
Although in vivo genetic editing research is very much present and abundant 
today, a majority of the research focuses on somatic cell editing, such as the cancer 
and metabolic disease studies discussed earlier. I propose that shifting some 
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attention to in vivo germline genetic editing would prove fruitful in efforts to produce 
more accepted genetic editing techniques. The next section will focus on in vivo 
germline genetic editing and investigate its efficiency compared to in vitro genetic 
editing.  In vivo germline editing could manifest itself as editing the sperm or eggs 
themselves, or editing the cells that produce sperm and eggs. In vivo genetic editing 
of germline cells would potentially address the Christian concern for the conjugal act 
in the creation of future progeny, as it would allow for the editing of egg and 
sperm/sperm producing cells within an individual prior to the conjugal act. These 
techniques could be helpful for individuals who are concerned about a need for the 
conjugal act but want to fulfill their role as stewards and protect their progeny via 
protecting them from a certain heritable disease.  
Conclusion 
With the previously identified tensions zones within Christian discourse of 
genetic editing in mind, possible paths of genetic research can be identified to help 
develop more accepted genetic editing practices (epigenetics, somatic gene therapy, 
in-vivo genetic editing and adult genetic editing) that appeal to the Christian 
stewardship goal of prevention of harm and the need for the conjugal act in the 
creation of new life. Amongst the analysis of possible research paths, I identified a 
concerning lack of attention towards somatic genetic editing’s potential risk of 
maternal transduction, when the editing mechanism vector spreads from fetus to 
mother. Although this lack of concern allows for more potential genetic editing paths 
that the Christian body could potentially accept, it should not go unquestioned. 
Further inquiries as to why exactly the Christian community is not worrying about the 
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maternal body when considering risk assessment should be considered. The next 
section will examine current data on off-target effects of CRISPR-Cas9 genetic 
editing and propose an experiment to understand if the off-target affects will change 
when in vivo verses in vitro.    
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CHAPTER 3. 
AN ANALYSIS OF IN VIVO AND IN VITRO CRISPR-CAS9 
EFFICIENCY 
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Introduction  
Today, the pages of online health blogs to Time Magazine are filled with the 
general public in discussion of genetic editing. The focus of these conversations 
varies between bioethical concerns, efficiency, and safety for clinical application on 
humans. As discussed in the previous chapters, since the launch of CRISPR, 
genetic editing has been a hot topic within Christian communities; a major Christian 
concern with genetic editing and its usage is the lack of the “conjugal act” in current 
genetic editing of future progeny. For example, commonly paired with genetic editing 
of embryos is in vitro fertilization (IVF), which forgoes an explicit need for the 
heterosexual sex, but instead is efficiently accomplished with the fertilization of an 
egg with a sperm sample in a laboratory setting. In efforts to develop more forms of 
genetic editing that communities are comfortable with and therefore allow genetic 
editing to be more accessible to these patients, I propose that comparing the 
efficiency of in vivo and in vitro CRISPR genetic editing will help form a basis for 
further research and possibly development of in vivo germline editing. This form of 
genetic editing is the topic of analysis for this study, as it relieves a Christian concern 
about the need for the “conjugal act” in the creation of new life. 
         In order to attest to the efficiency of in vivo CRISPR genetic editing in 
comparison to in vitro, this study will analyze current research on in vitro genetic 
editing and suggested optimizations and then apply this information in the 
development of the experiential design. This proposal will offer a study that will 
analyze both on-target and off-target mutations, in addition to overall efficiency, in 
both in vivo and in vitro treatments. 
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On-target mutation efficiency 
         In order to test whether or not a genetic editing technique is in fact editing the 
intended sequences, the on-target mutation efficiency must be measured. Currently 
there are a variety of methods to do this: mismatch cleavage assay, high-resolution 
melting analysis (HRMA), heteroduplex mobility assay by PAGE, cleaved amplified 
polymorphic sequences (CAPS) analysis, Sanger sequencing, amplified fragment 
length polymorphisms (AFLP), and Fluorescent PCR-capillary gel electrophoresis 
(Zischewski, Fischer, & Bortesi, 2017). Each method has its own benefits and 
disadvantages but generally concern whether or not it can detect small indels, large 
indels, and substitutions. The methods that miss large indels are: HRMA and 
heteroduplex mobility assay by PAGE, while AFLP fails to detect small indels and 
Fluorescent PCR-capillary gel electrophoresis fails to detect substitutions. Although 
many kinds of mutations could be incorporated by HR depending on the donor DNA, 
small indels from NHEJ repair and substitutions from HR using a donor template are 
more common than large indels. This characteristic is because the CRISPR system 
relies on endogenous double-strand break repair pathways.  Thus, HRMA and/or a 
targeted sequencing method could detect the mutations.  
HRMA is an analysis method that concentrates on a target region, amplifies it 
with a fluorescent PCR and analyzes it via melting curves (Zischewski et al., 2017). 
This technique is dependent upon the fluorescence loss when the dyes are no 
longer attached to the dsDNA during thermal denaturation. These melting 
temperature curves are utilized to identify the specific nature of the allele 
(homozygous/heterozygous mutant/wildtype); the shifts of the curves represent a 
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variation of nucleotides (Thomas, Percival, Yoder, & Parant, 2014). In order to 
produce an optimal HRMA with high resolution, the amplicon size is suggested to be 
around 100 bp (Thomas et al., 2014, Zischewski et al., 2017). The same 
amplification products could later be used for other analysis methods because 
HRMA does not alter the sequence of the amplicons. If for some reason a large indel 
is expected, to account for the limitation of HRMA not detecting large indels, AFLP 
can be used to detect these larger mutations. The  
Some decreases in on-target efficiency can also be attributed to 
nonhomologous end joining (NHEJ) of sequences rather than the preferred method 
of donor DNA integration through homology-directed repair (HDR). In order to 
combat this efficiency deficit, I will utilize single-stranded donor DNA (ssDNA) 
instead of the common double-stranded DNA (dsDNA) as ssDNA has been shown 
to increase HDR efficiency in Cas9-mediated gene editing in human cells 
(Richardson, Ray, DeWitt, Curie, & Corn, 2016). The donor ssDNA is developed to 
be of optimal length that is complementary to the 3’ terminus of the cleaved DNA 
strand that is complementary to the target strand. This optimal donor ssDNA has 
been shown to increase HDR rates to up to 60% and should be incorporated within 
protocols when developing and/or investigating efficient methods of CRISPR genetic 
editing. 
Off-target effects 
 Ways to detect 
 The rate of off-target mutations is an essential factor dictating the potential 
usage of a certain method of genetic editing. For the purpose of measuring the off-
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target effects, there are both biased and unbiased methods of varying sensitivity. 
Biased approaches look at specific predicted sites, while unbiased approaches look 
at the whole genome. For this study, I propose to use a targeted sequence 
amplification, a popular biased method that amplifies and sequences previously 
identified segments that may contain off-target sites. These potential candidates for 
off-target mutations can be identified via sequence similarity to the Cas9 guide RNA 
sequence. Sequence analysis of amplified candidate regions can be performed via 
Sanger sequencing or next generation sequencing (NGS). Sanger sequencing 
becomes a bit impractical when there are many potential segments to sequence. 
Although the amount of off-target sites vary widely based off of the identity of the 
gRNA, the number of off-target mutations can range from 0-150 (Zischewski et al., 
2017). Digenome sequencing is an unbiased technique which utilizes Cas9 and 
sgRNA in vitro to scan for potential off-target sites that can be used in the targeted 
sequence amplification, later sequenced via NGS (Zischewski et al., 2017). This 
method uses the combination of cell-free genomic DNA, Cas9, and sgRNA to 
identify both the target and off-target sites that are cleaved and measures the 
frequencies of unintended indels. Digenome sequencing has many benefits that 
include identifying off-target sites whose mutations occur at rate below 0.1% (Kim et 
al., 2015), incorporating multiple gRNA at once, and filtering out the cell’s own 
introduced double stranded breaks (DSBs). In order to be computationally identified, 
the DNA is digested to produce sequence reads with the same 5’ ends at cleavage 
sites (Kim et al., 2015). One identified setback of this method is that it is indeed 
being conducted in vitro rather than in vivo which could possibly lead to skewed 
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results (B. X. H. Fu, St. Onge, Fire, & Smith, 2016; Zischewski et al., 2017), but 
there is no evidence suggesting that off target effects for a particular guide RNA 
would differ between in vitro and in vivo systems.  
   Ways to minimize 
Unlike Zinc Finger Nucleases (ZFN) and transcription activator-like effector 
nucleases (TALENs) which are dimeric, CRISPR-Cas9 is monomeric which leads to 
a higher likelihood of off-target mutations because it scans for shorter target 
sequences. In addition, the sgRNA used can lead to off-target mutations, as certain 
sgRNAs can tolerate different amounts of mismatches (Zischewski et al., 2017). 
Because sgRNA sequence and length dictates potential off-target sites, it is an 
optimal component to modify in order to reduce off-target mutations (Frock et al., 
2015). For example, one could potentially minimize off-target effects by reducing the 
gRNA length from 20 nt to 17 or 18 nt to reduce the RNA-DNA binding energy (Y. Fu 
et al., 2013).  Finally, the nuclease can be engineered to make a double-stranded 
break via 2 separate single-stranded cuts by targeting two nearby sequences with a 
Cas9 cleavage mutant (a D10A mutant nickase version of Cas9n) (Ran et al., 2013). 
Methods and Experimental Design 
Goal of study. 
 The goal of the study is to quantify differences in CRISPR genetic editing 
efficiency, in regards to on-target mutations, off-target mutations, and overall 
efficiency between in vitro and in vivo editing of mouse eggs.  
 
 
		 54	
Mouse model.  
 In order to examine the efficiency of CRISPR genetic editing of eggs, the 
utilization of a fluorescent mouse model allows for simple detection of efficiency by 
physical examination of cultured cells. The mice used in this experiment will have 
been bred to express green fluorescent protein (GFP) throughout their bodies 
through methods established by Ikawa et al. For the in vitro treatment, pre-existing 
mouse cell lines expressing GFP will be used (Ikawa et al., 1995). These GFP 
expressing mice will then be mutated into BFP expressing mice via CRISPR-Cas9 
using HDR. Successful mutation will result in a blue fluorescence, while NHEJ will 
result in a loss of fluorescence due to the creation of small indels. 
 
Guide RNA. 
 As indicated by Liang et al. (2017), the guide RNA (sgRNA) to target the GFP 
gene will be designed and synthesized using GeneArt™ CRISPR gRNA Design Tool 
and Synthesis Kit. Qubit® RNA BR Assay Kit will be utilized to compute the 
concentration of sgRNA needed.  
 
Donor DNA.  
In order to easily identify the efficiency of gene editing in this model, a blue 
fluorescent protein (BFP) gene will be used as the donor DNA. Taking into 
consideration previous research on the higher rates of HDR when using ssDNA in 
comparison to dsDNA as donor DNA (Richardson et al., 2016), this designed BFP 
donor DNA will be single stranded. A correct targeting of the GFP sequence and 
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integration of the BFP donor DNA will result in the mouse egg cells emitting blue 
light when excited.   
 
CRISPR-Cas9 treatment. 
 In order to standardize the variables between the two treatments, the same 
CRISPR treatment system will be used for both. We will use the AAV serotype 8 
(AAV8) as a vector for the CRISPR- Staphylococcus aureus Cas9 (SaCas9) 
complex with the GFP sgRNA and an oocyte specific promoter, Gdf9 (Salvador, 
Silva, Kostetskii, Radice, & Strauss, 2008) (Figure 1). The AAV serotype is an 
Adeno-associated virus that infects humans. This delivery system has been shown 
effective for the delivery of CRISPR-cas9 systems into mouse skeletal and cardiac 
muscle, with this particular smaller Cas9 variant (Nelson et al., 2016). The AAV 
vector complex will be either directly microinjected into the oocyte region of the 
mouse for the in vivo treatment or transduced to the collection of harvested egg cells 
for the in vitro treatment. For the in vivo treatment, identification and surgical 
exposure of the female mouse reproductive tract protocol will be used from a study 
exploring mouse ovarian fat pads (Flesken-Nikitin, Harlan, & Nikitin, 2016).  
Figure 1. AAV8 vector and donor BFP ssDNA with induced mutation.  
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Off-target effects measurements. 
 A targeted sequencing approach can be utilized to measure off-target 
mutations in both in vivo and in vitro treatments. This approach will apply digenome 
sequencing to identify potential off-target sites that resemble the GFP sequence. 
Then, through targeted sequence amplification of the oocyte DNA, these targeted 
sites will be sequenced to determine if they were modified by the nuclease enzyme 
treatment. The oocytes used for amplification and analysis will either be from the in 
vitro CRISPR-Cas9 treatment or harvested from the in vivo treatment. The rates at 
which these potential off-target sites are modified in both in vivo and in vitro 
treatments can then be determined and compared (Figure 2). 
On-target mutation measurements. 
 To determine efficiency of the two treatment methods in regards to on target 
mutations, FACS will be used to determine the rate of on-target mutations. For the in 
vitro treatment, the edited unfertilized oocytes will be analyzed through FACS for 
fluorescence expression. The in vivo edited oocytes will be harvested after CRISPR 
treatment and similarly analyzed via FACS for fluorescence under the appropriate 
wavelengths (Figure 2). 
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Expected Results and Analysis 
Off-target mutations.  
 Off-target mutation rates allow for a quantification of the likelihood of the 
CRISPR complexes to create an unintended mutation at a sequence other than the 
target. These rates will be obtained through targeted sequence amplification of the 
regions identified by digenome sequencing. A two-tailed t-test will be used to 
statistically compare the means of off-target mutation rates from the in vivo and in 
vitro treatments. We do not expect to observe a significant difference in the ratio of 
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off-target/on-target mutations between the two treatments, as the same gRNA, 
donor DNA, and vectors are used. However, we may observe a reduction in the 
number of observed off-target mutation in the in vivo treatment, if there is an overall 
reduction of efficiency.  
 
On-target mutations. 
 A quantification of how often the CRISPR complex is both cutting the correct 
sequence and effectively incorporating the donor DNA is vital to future claims 
regarding the efficiency of CRISPR and its potential clinical use. The in vivo and in 
vitro on-target rates will be compared via a two-tailed t-test and analyzed to 
determine statistically significant difference. For example, we will compare the 
fraction of BFP-expressing cells, GFP-expressing cells, cells lacking fluorescence 
between the two treatments. The on-target rates will be characterized by the 
appearance of BFP. Although the essential requirements for CRISPR to perform 
efficiently within a cell are met in both the in vivo and in vitro treatments and in 
theory the on-target mutation rates would not vary significantly between the two, in 
vivo delivery may pose a problem. If the CRISPR delivery or exposure is 
compromised via the nature of in vivo delivery, we could expect to see a lower on-
target rate and off-target rate amongst the in vivo treatment. However, this result 
would not negate further in vivo genetic editing research, but could instead point to a 
need for further research of effective in vivo CRISPR complex delivery.  
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Overall efficiency. 
While off-target rates are characterized as off-target per on-target mutation, 
the overall efficiency reflects the overall amount of mutations, any change at all. In 
regards to our fluorescence test, this would resemble any change from green to 
either blue or non-fluorescence. Although the off-target and on-target may not vary 
between the two treatments, the total efficiency should be analyzed. This information 
can then be useful when determining the current clinical viability of in vivo genetic 
editing of oocytes. If the efficiency is lower but the off-target rate is the same or 
lower, this may be interpreted as a low-risk situation.  
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CONCLUSION  
	 In the first chapter of this thesis I examined current conservative Christian 
discourse on genetic editing and located four major Christian concerns commonly 
used in the Christian rejection of genetic editing research and clinical usage. These 
concerns (beginning of life, Creator-human relationship, imago Dei, and 
stewardship) are also tension zones within the discourse that contain contradictions 
and allow for the possibility of potential acceptance of genetic editing. In the second 
chapter, I applied this knowledge of tension zones to argue that two areas in which 
there is considerable possibility of Christian acceptance of genetic editing are the 
stewardship concern of harm and the conjugal act requirement in the creation of new 
life. I propose that epigenetics, somatic gene therapy and in vivo genetic editing are 
promising research fields that could help produce genetic editing methods that 
accommodate previously identified Christian concerns. The final chapter is an 
experimental proposal for an analysis of in vivo and in vitro CRISPR-Cas9 genetic 
editing efficiency; here efficiency is quantified by both on- and off-target mutation 
rates which quantify the amount of correct mutations at the targeted location and the 
amount of mutations at different similar-looking sites. This study is important when 
determining the clinical possibility of in vivo genetic editing and whether the risks out 
way the benefits.   
 This thesis is important as it shows that not only is it possible to study a 
specific discourse to determine important community concerns, but also that it is 
possible to scientifically pursue techniques that accommodate these concerns and 
allow for wider acceptance. Further studies in the three research fields I proposed 
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would support a greater goal of increasing the clinical accessibility of genetic editing. 
This is especially important for those who find themselves in situations where they 
would like to have the choice of genetic editing but are currently uncomfortable with 
contemporary methods. Not only is scientific research important in motivating this 
goal, but also religious studies research is important. Further analysis of other, non-
majority religious discourse regarding genetic editing will help us understand their 
concerns and develop research paths that can help accommodate those concerns, 
producing clinical genetic editing methods that they would feel more comfortable 
using.  
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